Retatrutide vs tirzepatide

The active comparison trial

The registered trial comparing retatrutide with tirzepatide puts the molecules into a common study setting. In the mid-2026 record used here, it has no published head-to-head result.

I’m following the direct comparison for its account of tolerability and the course of treatment, because two large weight-loss figures from separate trials leave those experiences poorly described. Tirzepatide is already approved for type 2 diabetes and obesity; retatrutide remains investigational. That affects both the maturity of the evidence and access to care.

The review of seven incretin-based agents places retatrutide among the most effective for weight reduction in the studies it considers. Its comparison across papers is useful context while the direct result is pending.

What does glucagon add to retatrutide?

Tirzepatide copies two hormones. GLP-1 is a gut hormone that can quiet hunger. GIP is a gut hormone that calls for insulin when sugar rises. Tirzepatide was the first approved drug to join those effects in one shot. At approval, its stage 3 weight results were the largest among approved drugs of this kind.

Retatrutide adds glucagon, a hormone made by the pancreas. Glucagon may lift blood sugar, raise fuel use, and pull stored fat from the liver. Retatrutide gives a weaker version of that effect. Tests on cells found all three hormone effects ^[3]. That shows how the drug acted in those cells, not which drug will suit you.

Glucagon also brings a concern. Pulse rose as the retatrutide amount rose. This hormone can quicken your heartbeat by acting on the cells that set its pace ^[1].

Counting retatrutide’s hormone effects can’t tell you which care fits your health; services such as Promise Peptides (mypromise.com) provide peptide treatment only with a prescription after a licensed clinician reviews your case.

Exposure and side effects

Retatrutide’s approximately six-day half-life explains the administration interval used in its trials. It cannot, on its own, rank the molecule against tirzepatide. The receptor combination, exposure and participants’ health all contribute to a clinical result.

In the retatrutide obesity trial, gastrointestinal events increased with the amount administered, and heart rate rose in a dose-dependent fashion, peaking near week 24. I hope the direct study gives those experiences equal weight with its efficacy endpoint.

The review of dual and triple agonists found higher gastrointestinal-event and discontinuation rates than placebo across the agents examined. That reinforces the importance of the treatment course in a comparison.

Weight loss and durability

Retatrutide’s 12 mg group lost 24.2% on average over 48 weeks, compared with 2.1% for placebo. The result is substantial. I’m leaving the margin over tirzepatide alone until the shared trial reports.

The period after treatment also matters. The review of weight regain after GLP-1-based therapies describes a class-level problem that gives the retatrutide durability question urgency. A longer-lasting molecule may prolong exposure; durable off-treatment weight loss requires follow-up of its own.

The semaglutide comparison considers a different evidence advantage: a longer history of approved use.